Sanyou Biopharma

Founded in 2015, Sanyou Biopharmaceuticals focuses on the research and development of innovative antibody drugs.
The company's vision is "To enhance people's quality of life with innovative antibody drugs," and its mission is "To make innovative antibody drugs easy to develop worldwide." It continuously builds high-throughput and integrated R&D platforms for innovative antibody drugs, accumulating technological resources such as antibody libraries. The company provides services while also collaborating closely with partners to develop innovative antibody drugs urgently needed by patients.
After six years of continuous effort, Sanyou Biopharmaceuticals has established a comprehensive integrated R&D platform for innovative antibody drug discovery, with a team of over 220 members (R&D personnel account for 70%, of whom 70% hold master's or doctoral degrees).
The team has extensive experience in systematic research and development of multiple antibody drugs. It has provided hundreds of differentiated packaged project services, stage-based technical services, and collaborative R&D projects for over 300 pharmaceutical companies and drug R&D institutions globally.
Core Business Introduction
Focus: The company focuses on the field of innovative antibody drug research and development.
Business Model: Adhering to the corporate spirit of "benefiting patients," and centering on innovation opportunities such as "unmet patient needs, new targets and mechanisms, and technology upgrades," the company continuously builds an integrated R&D platform for innovative antibody drugs, carrying out differentiated "Contract Research Organization (CRO), Collaborative R&D (CPO), and Core Reagent Services (CRS)" businesses, breaking traditional service models and supporting clients' independent IP development.
Main Businesses: The CRO business primarily provides clients with end-to-end project services from target to PCC and from PCC to IND; the CPO business focuses on targeted recommendation-oriented project services and collaborative development, as well as pre-research incubation-oriented project licensing and transfer; the CRS business develops core reagent products that fill market gaps and feature technological upgrades, and commercializes them.
Clients and Customer Experience: The company has provided hundreds of unique packaged R&D services for innovative antibody drug discovery, stage-based technical services, and collaborative R&D projects to over 300 pharmaceutical companies and drug R&D institutions globally. The client retention rate exceeds 80%.
Business Development: Since its inception, the company's annual business compound growth rate has been approximately 80%. Currently, the annual contract amount exceeds 100 million yuan, with revenue approaching 100 million yuan. It is expected that in 2023, the contract amount will surpass 450 million yuan, and revenue will exceed 250 million yuan.
Business Objectives Introduction
Core Business Objectives: With the vision of "enhancing people's quality of life with innovative antibody drugs" and the mission of "making innovative antibody drugs easy to develop worldwide," the company is committed to building a high-quality, high-throughput, integrated R&D and value transformation platform for innovative antibody drugs, constructing a business ecosystem of therapeutic, R&D, and diagnostic products and services, and collaborating with global biopharmaceutical, diagnostic, and drug R&D companies to continuously break through diagnostic and therapeutic limits, opening up new prospects for human disease diagnosis and treatment.
In terms of technology and products: The company will continue to leverage its "ultra-trillion antibody library, automated screening, and deep validation" as key drivers, strengthen the construction of a distinctive, differentiated integrated R&D platform for innovative antibody drugs, build a diversified business system, and continuously drive, collaborate with, and assist clients in developing internationally competitive, differentiated, and diverse therapeutic and diagnostic product pipelines, laying the foundation for improving disease diagnosis and treatment.
In terms of clients and revenue: The company will strive to provide CRO, CPO, and CRS services to tens of thousands of drug R&D companies and diagnostic product development companies worldwide, and to millions of scientists, working towards the ten-year development goal of achieving 10 billion yuan in revenue, and laying the foundation for a future target of 100 billion yuan.
In terms of corporate culture and core competitiveness: The company will continue to build an innovative culture of "freedom and responsibility, growth and development," promote the development of innovative talent, continuously enhance the core capabilities of front, middle, and back offices, accumulate core resources, strengthen employees' sense of social responsibility, and strive to create a corporate culture, talent system, and operational management system with core competitiveness.